175 related articles for article (PubMed ID: 31308061)
1. Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks.
Sundaravel S; Kuo WL; Jeong JJ; Choudhary GS; Gordon-Mitchell S; Liu H; Bhagat TD; McGraw KL; Gurbuxani S; List AF; Verma A; Wickrema A
Clin Cancer Res; 2019 Sep; 25(18):5638-5649. PubMed ID: 31308061
[TBL] [Abstract][Full Text] [Related]
2. Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes.
Sundaravel S; Duggan R; Bhagat T; Ebenezer DL; Liu H; Yu Y; Bartenstein M; Unnikrishnan M; Karmakar S; Liu TC; Torregroza I; Quenon T; Anastasi J; McGraw KL; Pellagatti A; Boultwood J; Yajnik V; Artz A; Le Beau MM; Steidl U; List AF; Evans T; Verma A; Wickrema A
Proc Natl Acad Sci U S A; 2015 Nov; 112(46):E6359-68. PubMed ID: 26578796
[TBL] [Abstract][Full Text] [Related]
3. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q.
Zhou L; Opalinska J; Sohal D; Yu Y; Mo Y; Bhagat T; Abdel-Wahab O; Fazzari M; Figueroa M; Alencar C; Zhang J; Kambhampati S; Parmar S; Nischal S; Hueck C; Suzuki M; Freidman E; Pellagatti A; Boultwood J; Steidl U; Sauthararajah Y; Yajnik V; McMahon C; Gore SD; Platanias LC; Levine R; Melnick A; Wickrema A; Greally JM; Verma A
J Biol Chem; 2011 Jul; 286(28):25211-23. PubMed ID: 21532034
[TBL] [Abstract][Full Text] [Related]
4. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
Pellagatti A; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jädersten M; Killick S; Verma A; Norbury CJ; Hellström-Lindberg E; Wainscoat JS; Boultwood J
Leukemia; 2010 Apr; 24(4):756-64. PubMed ID: 20220779
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells.
Ruiz-Gutierrez M; Bölükbaşı ÖV; Alexe G; Kotini AG; Ballotti K; Joyce CE; Russell DW; Stegmaier K; Myers K; Novina CD; Papapetrou EP; Shimamura A
JCI Insight; 2019 Apr; 5(12):. PubMed ID: 31039138
[TBL] [Abstract][Full Text] [Related]
6.
Muench DE; Ferchen K; Velu CS; Pradhan K; Chetal K; Chen X; Weirauch MT; Colmenares C; Verma A; Salomonis N; Grimes HL
Blood; 2018 Nov; 132(21):e24-e34. PubMed ID: 30249787
[TBL] [Abstract][Full Text] [Related]
7. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS.
An N; Khan S; Imgruet MK; Gurbuxani SK; Konecki SN; Burgess MR; McNerney ME
Blood; 2018 Jun; 131(24):2682-2697. PubMed ID: 29592892
[TBL] [Abstract][Full Text] [Related]
8. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
9. Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes.
Stevens BM; Khan N; D'Alessandro A; Nemkov T; Winters A; Jones CL; Zhang W; Pollyea DA; Jordan CT
Nat Commun; 2018 Sep; 9(1):3694. PubMed ID: 30209285
[TBL] [Abstract][Full Text] [Related]
10. What is the role of the microenvironment in MDS?
Calvi LM; Li AJ; Becker MW
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101113. PubMed ID: 31779976
[TBL] [Abstract][Full Text] [Related]
11. Honokiol Inhibits Constitutive and Inducible STAT3 Signaling via PU.1-Induced SHP1 Expression in Acute Myeloid Leukemia Cells.
Bi L; Yu Z; Wu J; Yu K; Hong G; Lu Z; Gao S
Tohoku J Exp Med; 2015 Nov; 237(3):163-72. PubMed ID: 26466521
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndrome hematopoietic stem cell.
Li J
Int J Cancer; 2013 Aug; 133(3):525-33. PubMed ID: 23047726
[TBL] [Abstract][Full Text] [Related]
13. Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes.
Kalina U; Hofmann WK; Koschmieder S; Wagner S; Kauschat D; Hoelzer D; Ottmann OG
Exp Hematol; 2000 Oct; 28(10):1158-63. PubMed ID: 11027834
[TBL] [Abstract][Full Text] [Related]
14. Dock4 is regulated by RhoG and promotes Rac-dependent cell migration.
Hiramoto K; Negishi M; Katoh H
Exp Cell Res; 2006 Dec; 312(20):4205-16. PubMed ID: 17027967
[TBL] [Abstract][Full Text] [Related]
15. DOCK4 stimulates MUC2 production through its effect on goblet cell differentiation.
Qin T; Yang J; Huang D; Zhang Z; Huang Y; Chen H; Xu G
J Cell Physiol; 2021 Sep; 236(9):6507-6519. PubMed ID: 33559155
[TBL] [Abstract][Full Text] [Related]
16. Nuclear translocation of PKC-α is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs).
Poli A; Ratti S; Finelli C; Mongiorgi S; Clissa C; Lonetti A; Cappellini A; Catozzi A; Barraco M; Suh PG; Manzoli L; McCubrey JA; Cocco L; Follo MY
FASEB J; 2018 Feb; 32(2):681-692. PubMed ID: 28970249
[TBL] [Abstract][Full Text] [Related]
17. PI3-kinase deletion promotes myelodysplasia by dysregulating autophagy in hematopoietic stem cells.
Ames K; Kaur I; Shi Y; Tong MM; Sinclair T; Hemmati S; Glushakow-Smith SG; Tein E; Gurska L; Steidl U; Dubin R; Shan J; Montagna C; Pradhan K; Verma A; Gritsman K
Sci Adv; 2023 Feb; 9(8):eade8222. PubMed ID: 36812307
[TBL] [Abstract][Full Text] [Related]
18. Dephosphorylation of ZAP-70 and inhibition of T cell activation by activated SHP1.
Brockdorff J; Williams S; Couture C; Mustelin T
Eur J Immunol; 1999 Aug; 29(8):2539-50. PubMed ID: 10458769
[TBL] [Abstract][Full Text] [Related]
19. Differential Lyn-dependence of the SHIP1-deficient mast cell phenotype.
Nunes de Miranda SM; Wilhelm T; Huber M; Zorn CN
Cell Commun Signal; 2016 May; 14(1):12. PubMed ID: 27206658
[TBL] [Abstract][Full Text] [Related]
20. Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes.
Paracatu LC; Schuettpelz LG
Front Immunol; 2020; 11():1236. PubMed ID: 32625214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
